Google
DNA — GINKGO BIOWORKS HOLDINGS (Healthcare >> Biotechnology)
DNA FAQ
What is DNA's ROE?
GINKGO BIOWORKS HOLDINGS reports a Return on Equity (ROE) of -68.69%.
What is DNA's dividend yield?
GINKGO BIOWORKS HOLDINGS offers a dividend yield of 0.00%.
What is DNA's Deepscope Quality Score?
Deepscope rates DNA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DNA?
Deepscope's AI Timing Score for DNA is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DNA belong to?
GINKGO BIOWORKS HOLDINGS is classified under the Healthcare >> Biotechnology sector on the NYSE exchange.
|
USD 8.22
Price
-0.83
(-9.17%)
Day Change
|
|
|---|
DNA, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.22 |
| PBV / Sector |
1.23 / 4.63
GOOD
|
| Earning Per Share | -4.59 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
11.58 M
GREAT
|
| Average 1W Daily Value |
18.96 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:36 |
| Symbol | DNA |
| Name | GINKGO BIOWORKS HOLDINGS |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 53.36 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 544.81 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 27 Drydock Avenue, Boston, MA, United States, 02210
Phone: 877 422 5362
Website: https://www.ginkgo.bio
Employees: 485
Sector: Healthcare >> Biotechnology
Description: Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
